Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

05 Mar 2010
Director/PDMR Shareholding

March 5, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company (the “Company”), announces that March 5, 2010, it was notified by Mr Matthew Emmens, Chairman of the Company, of the exercise, on March 2, 2010, of options over 590,834 Shire ordinary shares of 5p (“Shares”). Mr Emmens chose to use a net settled cashless exercise facility run by the Company.

Number of Shares under option

Exercise price

Number of Shares received

Number of Shares lapsed

305,345

£5.26 

194,425

110,920

285,489

£5.585

175,374

110,115

In addition the Company was notified by Mr Emmens on March 5, 2010 of the following sale of Shares:

Date of sale

Number of Shares sold

Average sale price

March 2, 2010

165,213*

£14.48

March 3, 2010

204,586

£14.6177

*Shares sold to satisfy tax liabilities.

Following the above transactions, Mr Emmens holds 92,874 Shares and 94,163 ADSs. He also holds awards of Stock Appreciation Rights, Performance Shares and Restricted Shares over 296,744 ADSs. One ADS is equal to three Shares.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

Tony Guthrie
Deputy Company Secretary

 

For further information please contact:

Investor Relations

Cléa Rosenfeld (Rest of the World)

+44 1256 894 160

 

Eric Rojas (North America)

+1 617 551 9715

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

05 Mar 2010 Director/PDMR Shareholding (31KB PDF)

« Back to Shire news

Did you know...

You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.

Email and SMS alerts

Did you know...

We donated over $35,000 in
outdated laboratory
equipment
to local
schools?